Abstract
Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points
Highlights
To the Editor: We read with great interest the article published by Biquard and colleagues showing that, according to public transcriptomic data, the hepatic expression of angiotensin converting enzyme 2 (ACE2) and the cellular transmembrane protease serine 2 (TMPRSS2) remains unchanged in patients with metabolicassociated fatty liver disease (MAFLD).[1]
We have assessed the expression of SARS-CoV-2 cell entry molecules in the liver of obese patients with non-alcoholic fatty liver disease (NAFLD) and/or type 2 diabetes T2D, since this information seems crucial to understand and prevent cell infection
Liver mRNA expression of ACE2 was significantly lower in patients with T2D while TMPRSS2 tended to decrease but was not statistically significant (Fig. 1A)
Summary
To the Editor: We read with great interest the article published by Biquard and colleagues showing that, according to public transcriptomic data, the hepatic expression of angiotensin converting enzyme 2 (ACE2) and the cellular transmembrane protease serine 2 (TMPRSS2) remains unchanged in patients with metabolicassociated fatty liver disease (MAFLD).[1]. To the Editor: We read with great interest the article published by Biquard and colleagues showing that, according to public transcriptomic data, the hepatic expression of angiotensin converting enzyme 2 (ACE2) and the cellular transmembrane protease serine 2 (TMPRSS2) remains unchanged in patients with metabolicassociated fatty liver disease (MAFLD).[1] SARS-CoV-2 attaches to cells by binding to its receptor ACE2.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
